Gilead/Bristol Hep C Combo Gets High Marks At EASL, But Its Future Is In Doubt

All eyes are on Gilead Sciences following the news it may not continue development of GS-7977 alongside Bristol-Myers Squibb’s daclatasvir, though the all-oral pairing produced impressive data in Phase II.